公开(公告)号：EP2663555A2

公开(公告)日：2013-11-20

申请号：EP12733896.0

申请日：2012-01-12

Applicant: VentiRx Pharmaceuticals, Inc. ,  Array Biopharma, Inc.

Inventor： HOWBERT, James, Jeffry ,  HERSHBERG, Robert ,  BURGESS, Laurance E. ,  DOHERTY, George A. ,  EARY, Charles Todd ,  GRONEBERG, Robert D. ,  JONES, Zachary ,  LYSSIKATOS, Joseph P. ,  YANG, Hong Woon

IPC: C07D403/10 ,  C07D403/12 ,  C07D223/14 ,  A61K31/55 ,  A61P37/00

CPC classification number: C07D223/16 ,  C07D243/14 ,  C07D401/12 ,  C07D487/04

Abstract: Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, fibrotic disease, cardiovascular disease, infectious disease, inflammatory disorder, graft rejection, or graft-versus-host disease.

公开(公告)号：EP1934228A2

公开(公告)日：2008-06-25

申请号：EP06813989.8

申请日：2006-08-31

Applicant: Array Biopharma, Inc.

Inventor： MIKNIS, Greg ,  LYSSIKATOS, Joseph P. ,  LAIRD, Ellen ,  TARLTON, Eugene ,  BUCKMELTER, Alexandre J. ,  REN, Li ,  RAST, Bryson ,  SCHLACTER, Stephen T. ,  WENGLOWSKY, Steven Mark

IPC: C07D495/04 ,  C07D491/04 ,  A61K31/4355 ,  A61K31/4365 ,  A61P35/00

CPC classification number: C07D491/04 ,  C07D495/04

Abstract: Compounds of Formula I are useful for inhibiting Raf kinase and for treating disorders mediated thereby. Methods of using compounds of Formula I, and stereoisomers, geometric isomers, tautomers, solvates and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

公开(公告)号：EP3207930A1

公开(公告)日：2017-08-23

申请号：EP16203755.0

申请日：2012-01-12

Applicant: VentiRx Pharmaceuticals, Inc. ,  Array Biopharma, Inc.

Inventor： HOWBERT, James, Jeffry ,  HERSHBERG, Robert ,  BURGESS, Laurence, E. ,  DOHERTY, George, A. ,  EARY, Charles Todd ,  GRONEBERG, Robert, D. ,  JONES, Zachary ,  LYSSIKATOS, Joseph P. ,  YANG, Hong Woon

IPC: A61K31/55 ,  A61P37/00 ,  C07D223/16 ,  C07D243/14 ,  C07D401/12 ,  C07D487/04

CPC classification number: C07D223/16 ,  C07D243/14 ,  C07D401/12 ,  C07D487/04

Abstract: Provided are compounds of formula (II) useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compounds have use in treating or preventing disease, including cancer, autoimmune disease, fibrotic disease, cardiovascular disease, infectious disease, inflammatory disorder, graft rejection, or graft-versus-host disease.

Abstract translation: 提供了用于调节通过Toll样受体TLR7和/或TLR8的信号转导的式（II）化合物。 该化合物可用于治疗或预防疾病，包括癌症，自身免疫疾病，纤维化疾病，心血管疾病，感染性疾病，炎症性疾病，移植排斥或移植物抗宿主疾病。

公开(公告)号：EP2057168A2

公开(公告)日：2009-05-13

申请号：EP07841737.5

申请日：2007-08-31

Applicant: Array Biopharma, Inc.

Inventor： BUCKMELTER, Alexandre J. ,  LYSSIKATOS, Joseph P. ,  MIKNIS, Greg ,  REN, Li ,  WENGLOWSKY, Steven Mark , 

IPC: C07D491/04 ,  A61K31/4741 ,  A61P35/00

CPC classification number: C07D491/04

Abstract: Compounds of Formulas (I), (IIA) and (IIIA) are useful for inhibiting Raf kinase and for treating disorders mediated thereby. Methods of using compounds of Formulas (I), (IIA) and (IIIA) and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

公开(公告)号：EP1567506A2

公开(公告)日：2005-08-31

申请号：EP03768789.4

申请日：2003-11-10

Applicant: Array Biopharma, Inc.

Inventor： WALLACE, Eli ,  TOPALOV, George ,  ZHAO, Qian ,  LYSSIKATOS, Joseph P.

IPC: C07D239/94 ,  C07D215/42 ,  A61K31/517 ,  A61K31/4706 ,  A61P31/18

CPC classification number: C07D417/14 ,  C07D239/94 ,  C07D401/12 ,  C07D403/12 ,  C07D405/04

Abstract: Cyanoguanidine quinazoline and cyanoamidine quinazolamine derivatives that are useful in the treatment of hyperproliferative diseases are disclosed. Use of the compounds of the invention to manufacture therapeutic compositions for the treatment of hyperproliferative diseases in mammals is also disclosed.